PD-L2在头颈部鳞状细胞癌免疫治疗预后评估中的意义

Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy

背景与目的:程序性死亡[蛋白]-1(programmed death-1,PD-1)单抗免疫治疗在头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)中的作用愈发重要,然而目前具有响应率低、缺乏预测性生物标志物的问题。本研究旨在确定程序性死亡[蛋白]配体-2(programmed death ligand-2,PD-L2)能否作为预测HNSCC中PD-1单抗免疫治疗获益情况的生物标志物。方法:收集50例接受PD-1单克隆抗体免疫治疗的中晚期HNSCC的组织标本及临床数据,采用免疫组织化学染色法分析程序性死亡[蛋白]配体-1(programmed death ligand-1,PD-L1)、PD-L2表达量,采用SPSS 26.0软件根据基本临床特征、PD-L1与PD-L2表达量分组统计并进行Kaplan-Meier生存分析,采用GraphPad Prism软件绘制生存曲线。结果:PD-L2在HNSCC患者中阳性表达率较高,有超过80%的患者肿瘤组织可检出PD-L2表达;PD-L2的表达量显著影响免疫治疗结局,PD-L2高表达的患者平均生存期为18.8(16.0~21.7)个月,而PD-L2低表达的患者平均生存期为11.0(9.1~12.8)个月,差异有统计学意义(P<0.05)。结论:PD-L2可作为评估HNSCC中PD-1单克隆抗体免疫治疗获益的生物标志物。

Background and purpose:Programmed death-1(PD-1)monoclonal antibody therapy plays an increasingly important role in the treatment of head and neck squamous cell carcinoma(HNSCC).However,low response rate and lack of predictive biomarkers are still the challenging problems.This study aimed to confirm that programmed death ligand-2(PD-L2)is a predictive biomarker for the outcome of HNSCC anti-PD-1 immunotherapy.Methods:The samples and clinical data of 50 HNSCC patients undergoing PD-1 monoclonal antibody immunotherapy were collected.Immunohistochemical staining was used to analyze the level of programmed death ligand-1(PD-L1)and PD-L2.Kaplan-Meier overall survivals were analyzed using SPSS 26.0 software,grouped by the basic clinical characteristics and the PD-L1 and PD-L2 levels.Survival curves were plotted using GraphPad Prism.Results:HNSCC had a relatively high expression rate of PD-L2 with more than 80%of cases detected as PD-L2 positive.The expression of PD-L2 significantly correlated with the clinical outcome of immunotherapy,with a mean survival of 18.8(16.0-21.7)months for patients with high PD-L2 expression and 11.0(9.1-12.8)months for patients with low PD-L2 expression,this difference being statistically significant.Conclusion:PD-L2 has the potential to be used as a predictive biomarker for HNSCC anti-PD-1 immunotherapy.